5 results on '"Koca, Süleyman Serdar"'
Search Results
2. Ginger extract suppresses the activations of NF-?B and Wnt pathways and protects inflammatory arthritis.
- Author
-
Öz, Burak, Orhan, Cemal, Tuzcu, Mehmet, Şahin, Nurhan, Özercan, İbrahim Hanifi, Öner, Pınar Demirel, Koca, Süleyman Serdar, Juturu, Vijaya, and Şahin, Kazım
- Subjects
EXPERIMENTAL arthritis ,NF-kappa B ,GINGER ,ARTHRITIS ,ENZYME-linked immunosorbent assay ,LABORATORY rats - Abstract
objective: Rheumatoid arthritis (RA) is a disabling inflammatory disorder. Ginger is used for food and medicine to treat arthralgia, sprains, and muscle aches. Anti-inflammatory effects of ginger have been observed. The aim of our study was to detect the effects of ginger on experimentally induced inflammatory arthritis. Methods: Female Wistar albino rats (n = 21) were randomly separated into three groups (control, arthritis, and arthritis + ginger). Arthritis was generated by an appropriate method using type 2 collagen and Freund's adjuvant (collagen-induced arthritis model). The ginger group was treated starting at the first collagen injection with ginger root extract for 32 days by oral gavage (50 mg/kg/daily). Interleukin (IL)-6, IL-17, tumor necrosis factor-α (TNF-α), sclerostin, dickkopf-related protein-1 (DKK-1), and obestatin serum levels were studied by enzyme-linked immunosorbent assay method. Tissue TNF-α, IL-17, cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-κB) levels were detected using the Western blot method. Results: Mean arthritis score and serum levels of TNF-α, IL-6, and IL-17 were significantly decreased in ginger group than in the arthritis group. Increased sclerostin serum level and decreased DKK-1 serum levels were detected in ginger group compared with arthritis group. The decreases of IL-17, TNF-α, COX-2, and NF-κB tissue levels were statistically significant in the ginger group compared with arthritis group. Histopathological evaluation of the ginger group showed a decrease in the inflammation score compared to arthritis group. Conclusion: It can be concluded that ginger has protective properties in the development of inflammatory arthritis. The antiarthritic acts of ginger are related to NF-κB activity and Wnt pathway. Thus, it may be suggested that ginger is a candidate to research in human RA treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic.
- Author
-
KALYONCU, Umut, PEHLİVAN, Yavuz, AKAR, Servet, KAŞİFOĞLU, Timuçin, KİMYON, Gezmiş, KARADAĞ, Ömer, DALKILIÇ, Ediz, ERTENLİ, Ali İhsan, KILIÇ, Levent, ERSÖZLÜ, Duygu, BES, Cemal, EMMUNGİL, Hakan, MERCAN, Rıdvan, EDİBOĞLU, Elif Durak, KANITEZ, Nilüfer, BİLGİN, Emre, ÇOLAK, Seda, KOCA, Süleyman Serdar, GÖNÜLLÜ, Emel, and KÜÇÜKŞAHİN, Orhan
- Subjects
COVID-19 pandemic ,RITUXIMAB ,PANDEMICS ,COVID-19 ,PATIENT compliance ,ARTHRITIS ,TERMINATION of treatment ,VISUAL analog scale - Abstract
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis.
- Author
-
YOLBAŞ, Servet, YILDIRIM, Ahmet, TEKTEMUR, Ahmet, ÇELİK, Zulfinaz Betül, ÖNALAN ETEM, Ebru, ÖZERCAN, İbrahim Hanifi, AKIN, Mehmet Mustafa, and KOCA, Süleyman Serdar
- Subjects
RHEUMATOID arthritis ,ARTHRITIS ,TREATMENT of arthritis ,AUTOIMMUNE diseases ,TUMOR necrosis factors - Abstract
Background/aim: The Wnt/ß-catenin pathway has important biological activities, including the differentiation of cells and joint formations. The aim of our study was to determine the effect of paricalcitol on experimentally induced arthritis. Materials and methods: Type II collagen combined with Freund's adjuvant was applied to induce arthritis in Wistar albino female rats. Paricalcitol (0.3 µg/kg daily) was subcutaneously injected starting 1 day after collagen applications (prophylactic group) or 1 day after the onset of arthritis (therapeutic group), until day 29. Results: The 29th day arthritis scores were lower compared to the 13th day scores in the paricalcitol groups (P < 0.05), while they were higher in the arthritis group (P < 0.05). Marked cartilage-bone destruction and extensive perisynovial inflammation were detected in the arthritis group. Decreased cartilage-bone destruction and perisynovial inflammation in the paws were observed in the paricalcitol groups. The tissue mRNA levels of DKK1, Wnt5a, and axin-2 were higher in the arthritis group than in the control group. In the paricalcitol groups, mRNA expressions were lower than in the arthritis group. Conclusion: The present study shows that the Wnt/ß-catenin signaling pathway is active in arthritis. Moreover, paricalcitol ameliorates arthritis via inhibiting the Wnt/ß-catenin pathway. Paricalcitol and the Wnt/ß-catenin pathway are candidates for research in human rheumatoid arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Sorafenib Reveals Anti-Arthritic Potentials in Collagen Induced Experimental Arthritis Model.
- Author
-
GÖZEL, Nevzat, ÇAKIRER, Maşallah, KARATAŞ, Ahmet, TUZCU, Mehmet, ÖZDEMİR, Fethi Ahmet, DAĞLI, Adile Ferda, ŞAHİN, Kazım, and KOCA, Süleyman Serdar
- Subjects
DRUG therapy for arthritis ,ARTHRITIS prevention ,BONE injuries ,CARTILAGE injuries ,SYNOVITIS ,SUBCUTANEOUS injections ,ANIMAL experimentation ,ARTHRITIS ,CELL receptors ,COLLAGEN ,HISTOLOGICAL techniques ,JOINTS (Anatomy) ,ORAL drug administration ,RATS ,STATISTICAL sampling ,WESTERN immunoblotting ,ENDOTHELIAL growth factors ,ETANERCEPT ,PHARMACODYNAMICS ,SORAFENIB ,DIAGNOSIS ,THERAPEUTICS - Abstract
Objectives: This study aims to examine the effects of sorafenib on a collagen-induced arthritis model. Materials and methods: The study included 50 randomly selected female Wistar-albino rats (8-10-week-old, weighing between 200 g to 250 g). The rats were divided into five equal groups as control, arthritis, etanercept, sorafenib high-dose, and sorafenib low-dose groups, respectively. Arthritis was induced by injecting mixed intradermal chicken type II collagen and incomplete Freund's adjuvant. Twenty-four hours after the advent of arthritis; rats in group 3 were injected subcutaneous etanercept (6 mg/kg/week), while those in groups 4 and 5 were given sorafenib (10 or 30 mg/kg/day) orally until they were sacrificed on the 34th day. The rat claws and trunk bloods were carefully examined to note perisynovial inflammation and cartilage/bone injury through histopathology. Tissue vascular endothelial growth factor (VEGF) and VEGF receptor levels were carefully checked using western blot analysis. Results: Analysis of the experimental data showed that collagen-induced arthritis decreased in treatments groups after 12-13 days and 34th day in contrast with the arthritis group. Histopathological examination revealed broad perisynovial inflammation and cartilage/bone break down in the arthritis group. Compared to the control group, tissue VEGF and VEGF receptor levels increased in the arthritis group. Sorafenib and etanercept decreased tissue VEGF and VEGF receptor levels, perisynovial inflammation, damage of cartilage/bone. Conclusion: Our findings indicate that sorafenib treatment ameliorates collagen-induced arthritis with anti-VEGF effectiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.